Equilis Prequenza
Active substance
ATC code
Species
Horses.
Indications
Active immunisation of horses from 6 months of age against equine influenza to reduce clinical signs and virus excretion after infection.
Onset of immunity: 2 weeks after the primary vaccination course. Duration of immunity: 5 months after the primary vaccination course,
1 year after the first revaccination.
Dose to be administered and administration route
Intramuscular use.
Allow the vaccine to reach room temperature before use.
Vaccination schedule:
Primary vaccination course
Administer one dose (1 ml), by intramuscular injection, according to the following schedule:
• Primary vaccination course: first injection from 6 months of age, second injection 4 weeks later.
Revaccination
It is recommended that a single booster dose should only be administered to horses that have already received a primary vaccination course using vaccines that contain the same types of equine influenza virus included in this vaccine. A primary vaccination course may be considered necessary in horses that have not been suitably primed.
The first revaccination (third dose) is given 5 months after the primary vaccination course. This revaccination results in immunity to equine influenza lasting at least 12 months.
The second revaccination is given 12 months after the first revaccination.
The alternate use, at 12 months interval, of a suitable vaccine against equine influenza, containing the strains A/equine-2/South Africa/4/03 and A/equine-2/Newmarket-2/93, is recommended to maintain immunity levels for the influenza component (see scheme).
In case of increased infection risk or insufficient colostrum intake, an additional initial injection can be given at the age of 4 months followed by the full vaccination programme (primary vaccination course at 6 months of age and 4 weeks later).
Adverse reactions
Horses:
Rare (1 to 10 animals / 10,000 animals treated): | Injection site swelling1, Injection site pain2. |
Very rare (<1 animal / 10,000 animals treated, including isolated reports): | Fever3, Lethargy3, Inappetence3, Hypersensitivity reaction4. |
1 A diffuse hard or soft swelling (max. diameter 5 cm), regressing within 2 days. A local reaction exceeding 5 cm and possibly persisting longer than 2 days may occur in very rare cases.
2 Pain at the injection site may result in temporary functional discomfort (stiffness).
3 Fever, sometimes accompanied by lethargy and inappetence, may occur for 1 day, and up to 3 days in exceptional circumstances.
4 Including anaphylaxis (sometimes fatal). If such a reaction occurs, appropriate treatment should be administered without delay.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
